At the 1st Immunotherapy of Cancer Conference ( ITOC ) at a sponsored symposium supported by BMS, Professor Höller highlights key IO therapies that are currently in development with a focus on those which modulate different immune pathways.

He goes on to discuss that various approaches to using I-O agents in combination with other complimentary I-O agents or different existing treatment modalities are currently under investigation to maximise patient outcome.

To view the slides fullscreen click the square and arrows button at the bottom right of the player.